|
ROSEVILLE, Calif.--(BUSINESS WIRE)--Dutton Associates updates its
coverage of Pluristem Therapeutics, Inc. (Nasdaq:PSTI
- News), with a
Speculative Buy rating and 12-month price target of $6.50. The 17-page
report by Dutton Associates senior analyst Denise T. Resnik is available
at www.jmdutton.com as well as
from First Call, Bloomberg, Zacks, Reuters, and Knobias and other
leading financial portals. Pluristem Therapeutics’
innovative cell therapy technology has the potential to enable blood
from the umbilical cord and the placenta (retrieved after the birth of a
baby) to become a viable alternative to stem cells harvested from donor
bone marrow, with its intrinsic problems. While validation of the
Company’s technology is still in the
pre-clinical stage, we believe that, if the technology proves to be
successful, the impact on the patient population requiring bone marrow
transplant would be significant, especially as therapeutic uses for such
transplants continue to be discovered. As the Company makes progress in
its clinical program — specifically filing for
Food and Drug Administration permission to conduct Phase 1 trials and
commencing those trials — we believe the
shares will respond favorably. About Dutton Associates
Dutton Associates is one of the largest independent
investment research firms in the U.S. Its 27 senior analysts are
primarily CFAs, have expertise in many industries. Dutton Associates
provides continuing analyst coverage of 110 enrolled companies, and its
research, estimates, and ratings are carried in all the major databases
serving institutions and online investors.
The current cost of enrollment in our one-year
continuing research program is US $35,000 prepaid for 4 Research
Reports, typically published quarterly, and requisite Research Notes.
Dutton Associates received $52,000 from the Company for 6 Research
Reports with coverage commencing on 9/6/06. The Firm does not accept any
equity compensation. Our principals and analysts are prohibited from
owning or trading in securities of covered companies. The views
expressed in this research report accurately reflect the analyst's
personal views about the subject securities or issuer. Neither the
analyst's compensation nor the compensation received by us is in any way
related to the specific ratings or views contained in this research
report or note. Please read full disclosures and analyst background at
www.jmdutton.com before investing
Contact:
Dutton Associates, LLC
John M. Dutton, 916-941-8119
Source: Pluristem
Therapeutics, Inc.
|
